Nebenwirkungen · Adcirca (previously Tadalafil Lilly)
ADCIRCA 2 mg/mL oral suspension · Abschnitt 4.8 · PDF-Seite 26
HOS-210153 · Präparat HOS-154449
In the pivotal placebo-controlled study of ADCIRCA for the treatment of PAH, a total of 323 patients were treated with ADCIRCA at doses ranging from 2.5 mg to 40 mg once daily and 82 patients were treated with placebo. The duration of treatment was 16 weeks. The overall frequency of discontinuation due to adverse events was low (ADCIRCA 11 %, placebo 16 %). Three hundred and fifty-seven (357) patients who completed the pivotal study entered a long-term extension study. Doses studied were 20 mg and 40 mg once daily.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-27T15:17:00Z · SHA-256 f45503711a580d9fd5973be63b2c67b7830a1e53d77892c603581b2f6ee084ab · Passage bdad2d685c548c1224cac4f50de612be6805367e5036cdbfb4dc59b8b39600cc · Zeichen 398–918 im Abschnitt